-Network: (0010 - Statement - Condensed Consolidated Statement of Earnings)

-Statement of Earnings {ID1}

Net Sales {ID2}

Cost of products sold {ID3}

Research and development {ID4}

Acquired in-process research and development {ID5}

Selling, general and administrative {ID6}

Total Operating Cost and Expenses {ID7}

Operating Earnings {ID8}

Interest expense {ID9}

Interest (income) {ID10}

(Income) from TAP Pharmaceutical Products Inc. joint venture {ID11}

Net foreign exchange loss (gain) {ID12}

Other (income) expense, net {ID13}

Earnings Before Taxes {ID14}

Taxes on Earnings {ID15}

Net Earnings {ID16}

Basic Earnings Per Common Share (in dollars per share) {ID17}

Diluted Earnings Per Common Share (in dollars per share) {ID18}

Cash Dividends Declared Per Common Share (in dollars per share) {ID19}

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) {ID20}

Dilutive Common Stock Options and Awards (in shares) {ID21}

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) {ID22}

Outstanding Common Stock Options Having No Dilutive Effect (in shares) {ID23}

-Network: (0020 - Statement - Condensed Consolidated Statement of Cash Flows)

-Statement of Cash Flows {ID24}

-Cash Flow From (Used in) Operating Activities {ID25}

Net earnings {ID26}

-Adjustments to reconcile earnings to net cash from operating activities - {ID27}

Depreciation {ID28}

Amortization of intangible assets {ID29}

Share-based compensation {ID30}

Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture {ID31}

Gain on dissolution of TAP Pharmaceutical Products Inc. joint venture {ID32}

Acquired in-process research and development {ID33}

Trade receivables {ID34}

Inventories {ID35}

Other, net {ID36}

Net Cash From Operating Activities {ID37}

-Cash Flow From (Used in) Investing Activities {ID38}

Acquisitions of property and equipment {ID39}

Acquisitions of businesses, net of cash acquired {ID40}

Proceeds from sales of Boston Scientific common stock {ID41}

Purchases of other investment securities, net {ID42}

Other, net {ID43}

Net Cash (Used in) Investing Activities {ID44}

-Cash Flow From (Used in) Financing Activities {ID45}

Proceeds from issuance of short-term debt and other {ID46}

Proceeds from issuance of long-term debt {ID47}

Repayments of long-term debt {ID48}

Purchases of common shares {ID49}

Proceeds from stock options exercised, including tax benefit {ID50}

Dividends paid {ID51}

Net Cash From (Used in) Financing Activities {ID52}

Effect of exchange rate changes on cash and cash equivalents {ID53}

Net Increase in Cash and Cash Equivalents {ID54}

Cash and Cash Equivalents, Beginning of Year {ID55}

Cash and Cash Equivalents, End of Period {ID56}

-Network: (0030 - Statement - Condensed Consolidated Balance Sheet)

-Balance Sheet {ID57}

-Assets {ID58}

-Current Assets {ID59}

Cash and cash equivalents {ID60}

Investments, primarily time deposits and certificates of deposit {ID61}

Trade receivables, less allowances of $299,234 in 2009 and $263,632 in 2008 {ID62}

-Inventories: {ID63}

Finished products {ID64}

Work in process {ID65}

Materials {ID66}

Total inventories {ID67}

Prepaid expenses, deferred income taxes, and other receivables {ID68}

Total Current Assets {ID69}

Investments {ID70}

Property and Equipment, at Cost {ID71}

Less: accumulated depreciation and amortization {ID72}

Net Property and Equipment {ID73}

Intangible Assets, net of amortization {ID74}

Goodwill {ID75}

Deferred Income Taxes and Other Assets {ID76}

Total Assets {ID77}

-Liabilities and Shareholders' Investment {ID78}

-Current Liabilities: {ID79}

Short-term borrowings {ID80}

Trade accounts payable {ID81}

Salaries, dividends payable, and other accruals {ID82}

Income taxes payable {ID83}

Obligation in connection with conclusion of TAP Pharmaceutical Products, Inc. joint venture {ID84}

Current portion of long-term debt {ID85}

Total Current Liabilities {ID86}

Long-term Debt {ID87}

Post-employment Obligations and Other Long-term Liabilities {ID88}

Commitments and Contingencies {ID89}

-Shareholders' Investment: {ID90}

Preferred shares, one dollar par value; Authorized - 1,000,000 shares, none issued {ID91}

Common shares, without par value; Authorized - 2,400,000,000 shares; Issued at stated capital amount - Shares: 2009: 1,607,948,710; 2008: 1,601,580,899 {ID92}

Common shares held in treasury, at cost - Shares: 2009: 62,036,267; 2008: 49,147,968 {ID93}

Earnings employed in the business {ID94}

Accumulated other comprehensive income (loss) {ID95}

Total Abbott Shareholders' Investment {ID96}

Noncontrolling Interests in Subsidiaries {ID97}

Total Equity {ID98}

Total Liabilities and Shareholders' Equity {ID99}

-Network: (0035 - Statement - Condensed Consolidated Balance Sheet Parenthetical)

-Balance Sheet {ID100}

Trade receivables allowances of $314,325 in 2009 and $263,632 in 2008 (in dollars) {ID101}

Preferred shares authorized (in shares) {ID102}

Preferred shares issued (in shares) {ID103}

Common shares authorized (in shares) {ID104}

Common shares issued (in shares) {ID105}

Common shares held in treasury (in shares) {ID106}

-Network: (1010 - Notes - Basis of Presentation)

-Notes to Financial Statements {ID107}

Basis of Presentation {ID108}

-Network: (1020 - Notes - Supplemental Financial Information)

-Notes to Financial Statements {ID109}

Supplemental Financial Information {ID110}

-Network: (1030 - Notes - Taxes on Earnings)

-Notes to Financial Statements {ID111}

Taxes on Earnings {ID112}

-Network: (1040 - Notes - Litigation and Environmental Matters)

-Notes to Financial Statements {ID113}

Litigation and Environmental Matters {ID114}

-Network: (1050 - Notes - Post-Employment Benefits)

-Notes to Financial Statements {ID115}

Post-Employment Benefits {ID116}

-Network: (1060 - Notes - Comprehensive Income, net of tax)

-Notes to Financial Statements {ID117}

Comprehensive Income, net of tax {ID118}

-Network: (1070 - Notes - Segment Information)

-Notes to Financial Statements {ID119}

Segment Information {ID120}

-Network: (1080 - Notes - Incentive Stock Program)

-Notes to Financial Statements {ID121}

Incentive Stock Program {ID122}

-Network: (1090 - Notes - Conclusion of TAP Pharmaceutical Products Inc. Joint Venture)

-Notes to Financial Statements {ID123}

Conclusion of TAP Pharmaceutical Products Inc. Joint Venture {ID124}

-Network: (1100 - Notes - Business Acquisitions)

-Notes to Financial Statements {ID125}

Business Acquisitions {ID126}

-Network: (1110 - Notes - Financial Instruments, Derivatives and Fair Value Measures)

-Notes to Financial Statements {ID127}

Financial Instruments, Derivatives and Fair Value Measures {ID128}

-Network: (1120 - Notes - Goodwill and Intangible Assets)

-Notes to Financial Statements {ID129}

Goodwill and Intangible Assets {ID130}

-Network: (1130 - Notes - Restructuring Plans)

-Notes to Financial Statements {ID131}

Restructuring Plans {ID132}

-Network: (1140 - Notes - Subsequent Event - Litigation Settlement)

-Notes to Financial Statements {ID133}

Subsequent Event - Litigation Settlement {ID134}

-Network: (9999 - Other Information - Document and Entity Information)

-Document and Entity Information {ID135}

Document Type {ID136}

Document Period End Date {ID137}

Amendment Flag {ID138}

Amendment Description {ID139}

Entity Registrant Name {ID140}

Entity Central Index Key {ID141}

Entity Current Reporting Status {ID142}

Entity Voluntary Filers {ID143}

Current Fiscal Year End Date {ID144}

Entity Filer Category {ID145}

Entity Well-known Seasoned Issuer {ID146}

Entity Common Stock, Shares Outstanding {ID147}

Entity Public Float {ID148}

ABBOTT LABORATORIES XBRL Taxonomy Presentation Networks